Clinical implications of biological markers in pancreatic ductal adenocarcinoma

Surgical Oncology

Volumn 21, Issue 4, 2012, Pages

  Giovinazzo, Francesco ^a,b   Turri, Giulia ^a   Zanini, Sara ^a   Butturini, Giovanni ^b   Scarpa, Aldo ^b   Bassi, Claudio ^a,b  

^a Laboratory of Translational Surgery   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Cancer biology; Neoplastic molecular markers; Pancreatic cancer; Pancreatic surgery

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; BRCA2 PROTEIN; CAVEOLIN 1; CETUXIMAB; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DJ 1 PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; ERLOTINIB; GEMCITABINE; HEAT SHOCK PROTEIN 27; K RAS PROTEIN; MATRIX METALLOPROTEINASE; MESOTHELIN; MUCIN 1; OXALIPLATIN; PROSTATE STEM CELL ANTIGEN; PROTEIN P53; SALIRASIB; SCATTER FACTOR RECEPTOR; SMAD4 PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHEMORADIOTHERAPY; CLINICAL PRACTICE; DRUG TOLERABILITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREATICODUODENECTOMY; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SURVIVAL RATE; TELOMERE SHORTENING;

BIOLOGICAL MARKERS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84867849103     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2012.07.004     Document Type: Review

References (126)

1. R.H. Hruban, N.V. Adsay, J. Albores-Saavedra, C. Compton, E.S. Garrett, and S.N. Goodman Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions Am J Surg Pathol 25 2001 579 586
2. S.F. Sener, A. Fremgen, H.R. Menck, and D.P. Winchester Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database J Am Coll Surg 189 1999 1 7
3. K.D. Lillemoe, C.J. Yeo, and J.L. Cameron Pancreatic cancer: state-of-the-art care CA Cancer J Clin 50 2000 241 268
4. B. Haugk Pancreatic intraepithelial neoplasia - can we detect early pancreatic cancer? Histopathology 57 2010 503 514
5. R.H. Hruban, M. Goggins, J. Parsons, and S.E. Kern Progression model for pancreatic cancer Clin Cancer Res 6 2000 2969 2972
6. D. Antonello, S. Gobbo, V. Corbo, B. Sipos, N.R. Lemoine, and A. Scarpa Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma Pancreatology 9 2009 25 33
7. A.V. Biankin, J.G. Kench, F.P. Dijkman, B. Sipos, N.R. Lemoine, and A. Scarpa Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma Pathology 35 2003 14 24
8. C.J. Magee, W. Greenhalf, N. Howes, P. Ghaneh, and J.P. Neoptolemos Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications Surg Oncol 10 2001 1 23
9. A.G. Bodnar, M. Ouellette, M. Frolkis, S.E. Holt, C.P. Chiu, and G.B. Morin Extension of life-span by introduction of telomerase into normal human cells Science 279 1998 349 352
10. C.B. Harley, A.B. Futcher, and C.W. Greider Telomeres shorten during ageing of human fibroblasts Nature 345 1990 458 460
11. N.W. Kim, M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, and P.L. Ho Specific association of human telomerase activity with immortal cells and cancer Science 266 1994 2011 2015
12. T.M. Nakamura, G.B. Morin, K.B. Chapman, S.L. Weinrich, W.H. Andrews, and J. Lingner Telomerase catalytic subunit homologs from fission yeast and human Science 277 1997 955 959
13. M. Hashimoto, S. Kyo, X. Hua, S.L. Weinrich, W.H. Andrews, and J. Lingner Role of menin in the regulation of telomerase activity in normal and cancer cells Int J Oncol 33 2008 333 340
14. M. Meyerson Role of telomerase in normal and cancer cells J Clin Oncol 18 2000 2626 2634
15. R.C. O'Hagan, S. Chang, R.S. Maser, R. Mohan, S.E. Artandi, and L. Chin Telomere dysfunction provokes regional amplification and deletion in cancer genomes Cancer Cell 2 2002 149 155
16. Y. Hashimoto, Y. Murakami, K. Uemura, Y. Hayashidani, T. Sudo, and H. Ohge Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas J Gastrointest Surg 12 2008 17 28 [discussion 28-9]
17. Y. Hashimoto, Y. Murakami, K. Uemura, Y. Hayashidani, T. Sudo, and H. Ohge Detection of human telomerase reverse transcriptase (hTERT) expression in tissue and pancreatic juice from pancreatic cancer Surgery 143 2008 113 125
18. A. Nakashima, Y. Murakami, K. Uemura, Y. Hayashidani, T. Sudo, and Y. Hashimoto Usefulness of human telomerase reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy Pancreas 38 2009 527 533
19. F. Maire, S. Micard, P. Hammel, H. Voitot, P. Lévy, and P.H. Cugnenc Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA Br J Cancer 87 2002 551 554
20. E.S. Calhoun, J.B. Jones, R. Ashfaq, V. Adsay, S.J. Baker, and V. Valentine BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets Am J Pathol 163 2003 1255 1260
21. J.B. Koorstra, S.R. Hustinx, G.J. Offerhaus, and A. Maitra Pancreatic carcinogenesis Pancreatology 8 2008 110 125
22. H. Chen, H. Tu, Z.Q. Meng, Z. Chen, P. Wang, and L.M. Liu K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer Eur J Surg Oncol 36 2010 657 662
23. O. Mizuno, H. Kawamoto, N. Yamamoto, S. Horiguchi, K. Tsutsumi, and M. Fujii Single-pattern convergence of K-ras mutation correlates with surgical indication of intraductal papillary mucinous neoplasms Pancreas 39 2010 617 621
24. F. Kullmann, A. Hartmann, R. Stöhr, H. Messmann, M.M. Dollinger, and J. Trojan KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy Oncology 81 1 2011 3 8
25. D. Laheru, P. Shah, and N.V. Rajeshkumar Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer Invest New Drugs 2012 May 1
26. S. Weden, M. Klemp, I.P. Gladhaug, M. Moller, J.A. Eriksen, and G. Gaudernack Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras Int J Cancer 128 5 2011 Mar 1 1120 1128
27. R.E. Reiter, Z. Gu, T. Watabe, G. Thomas, K. Szigeti, and E. Davis Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer Proc Natl Acad Sci U S A 95 1998 1735 1740
28. A.G. de Nooij-van Dalen, G.A. van Dongen, S.J. Smeets, E.J. Nieuwenhuis, M. Stigter-van Walsum, and G.B. Snow Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma Int J Cancer 103 2003 768 774
29. C.P. Tran, C. Lin, and J. Yamashiro Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells Mol Cancer Res 1 2002 113 121
30. H. Sakamoto, K. Yoshimura, N. Saeki, H. Katai, T. Shimoda, and Y. Matsuno Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer Nat Genet 40 2008 730 740
31. N. Saeki, J. Gu, and T. Yoshida Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res 16 2010 3533 3538
32. P. Argani, C. Iacobuzio-Donahue, B. Ryu, C. Rosty, M. Goggins, and R.E. Wilentz Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 7 2001 3862 3868
33. D.M. McCarthy, A. Maitra, P. Argani, A.E. Rader, D.O. Faigel, and N.T. Van Heek Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases Appl Immunohistochem Mol Morphol 11 2003 238 243
34. P. Argani, C. Rosty, R.E. Reiter, R.E. Wilentz, S.R. Murugesan, and S.D. Leach Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma Cancer Res 61 2001 4320 4324
35. B. Terris, E. Blaveri, T. Crnogorac-Jurcevic, M. Jones, E. Missiaglia, and P. Ruszniewski Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas Am J Pathol 160 2002 1745 1754
36. J.A. Rodriguez, M. Li, Q. Yao, C. Chen, and W.E. Fisher Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications World J Surg 29 2005 297 305
37. M. Oliveira-Cunha, R.J. Byers, and A.K. Siriwardena Poly(A) RT-PCR measurement of diagnostic genes in pancreatic juice in pancreatic cancer Br J Cancer 104 2011 514 519
38. C. Caldas, S.A. Hahn, L.T. daCosta, M.S. Redston, M. Schutte, and A.B. Seymour Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nat Genet 8 1994 27 32
39. M. Schutte, R.H. Hruban, J. Geradts, R. Maynard, W. Hilgers, and S.K. Rabindran Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas Cancer Res 57 1997 3126 3130
40. A.A. Russo, L. Tong, J.O. Lee, P.D. Jeffrey, and N.P. Pavletich Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a Nature 395 1998 237 243
41. W.H. Liggett Jr., and D. Sidransky Role of the p16 tumor suppressor gene in cancer J Clin Oncol 16 1998 1197 1206
42. W.R. Sellers, J.W. Rodgers, and W.G. Kaelin Jr. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites Proc Natl Acad Sci U S A 92 1995 11544 11548
43. A.M. Goldstein, J.P. Struewing, A. Chidambaram, M.C. Fraser, and M.A. Tucker Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations J Natl Cancer Inst 92 2000 1006 1010
44. H.T. Lynch, R.E. Brand, D. Hogg, C.A. Deters, R.M. Fusaro, and J.F. Lynch Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome Cancer 94 2002 84 96
45. P. Singh, R. Srinivasan, and J.D. Wig Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment Pancreas 40 2011 644 652
46. J. Jeong, Y.N. Park, J.S. Park, D.S. Yoon, H.S. Chi, and B.R. Kim Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer Yonsei Med J 46 2005 519 525
47. D.T. Chang, C.H. Chapman, J.A. Norton, B. Visser, G.A. Fisher, and P. Kunz Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma Cancer 116 2010 5179 5187
48. G.M. Sclabas, J.G. Barton, T.C. Smyrk, D.A. Barrett, S. Khan, and M.L. Kendrick Frequency of subtypes of biliary intraductal papillary mucinous neoplasm and their MUC1, MUC2, and DPC4 expression patterns differ from pancreatic intraductal papillary mucinous neoplasm J Am Coll Surg 214 2012 27 32
49. B. Acres, and J.M. Limacher MUC1 as a target antigen for cancer immunotherapy Expert Rev Vaccines 4 2005 493 502
50. G.M. Sclabas, J.G. Barton, T.C. Smyrk, D.A. Barrett, S. Khan, and M.L. Kendrick MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition Oncogene 30 2011 1449 1459
51. T.L. Tinder, D.B. Subramani, G.D. Basu, J.M. Bradley, J. Schettini, and A. Million MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma J Immunol 181 2008 3116 3125
52. A. Westgaard, S. Tafjord, I.N. Farstad, M. Cvancarova, T.J. Eide, and O. Mathisen Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma BMC Cancer 8 2008 170
53. A. Westgaard, A.R. Schjolberg, M. Cvancarova, T.J. Eide, O.P. Clausen, and I.P. Gladhaug Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours Histopathology 54 2009 337 347
54. D.M. Besmer, J.M. Curry, L.D. Roy, T.L. Tinder, M. Sahraei, and J. Schettini Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis Cancer Res 71 2011 4432 4442
55. H. Kondo, S. Hazama, T. Kawaoka, S. Yoshino, S. Yoshida, and K. Tokuno Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes Anticancer Res 28 1B 2008 Jan-Feb 379 387
56. E.A. Musgrove, C.E. Caldon, J. Barraclough, A. Stone, and R.L. Sutherland Cyclin D as a therapeutic target in cancer Nat Rev Cancer 11 2011 558 572
57. S. Gansauge, F. Gansauge, M. Ramadani, H. Stobbe, B. Rau, and N. Harada Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis Cancer Res 57 1997 1634 1637
58. M. Kornmann, T. Ishiwata, J. Itakura, P. Tangvoranuntakul, H.G. Beger, and M. Korc Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival Oncology 55 1998 363 369
59. A. Kawesha, P. Ghaneh, A. Andren-Sandberg, D. Ograed, R. Skar, and S. Dawiskiba K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma Int J Cancer 89 2000 469 474
60. Q. Qiao, M. Ramadani, S. Gansauge, F. Gansauge, G. Leder, and H.G. Beger Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer Int J Cancer 95 2001 194 197
61. D.G. Kirsch, and M.B. Kastan Tumor-suppressor p53: implications for tumor development and prognosis J Clin Oncol 16 1998 3158 3168
62. M.S. Redston, C. Caldas, A.B. Seymour, R.H. Hruban, L. da Costa, and C.J. Yeo p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions Cancer Res 54 1994 3025 3033
63. N.A. Ottenhof, F.H. Morsink, F. Ten Kate, C.J. van Noorden, and G.J. Offerhaus Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only Cell Oncol (Dordr) 35 2012 119 126
64. C.H. Heldin, K. Miyazono, and P. ten Dijke TGF-beta signalling from cell membrane to nucleus through SMAD proteins Nature 390 1997 465 471
65. J. Massague, S.W. Blain, and R.S. Lo TGFbeta signaling in growth control, cancer, and heritable disorders Cell 103 2000 295 309
66. A.V. Biankin, A.L. Morey, C.S. Lee, J.G. Kench, S.A. Biankin, and H.C. Hook DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma J Clin Oncol 20 2002 4531 4542
67. C.A. Iacobuzio-Donahue, B. Fu, S. Yachida, M. Luo, H. Abe, and C.M. Henderson DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J Clin Oncol 27 2009 1806 1813
68. C.H. Crane, G.R. Varadhachary, J.S. Yordy, G.A. Staerkel, M.M. Javle, and H. Safran Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression J Clin Oncol 29 22 2011 Aug 1 3037 3043 [Epub 2011 Jun 27]
69. J.C. Wang DNA topoisomerases Annu Rev Biochem 65 1996 635 692
70. T.A. Jarvinen, and E.T. Liu Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes - molecular basis for combination chemotherapy in cancer Curr Cancer Drug Targets 6 2006 579 602
71. T.A. Jarvinen, M. Tanner, M. Barlund, A. Borg, and J. Isola Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer Genes Chromosomes Cancer 26 1999 142 150
72. D.E. Hansel, R. Ashfaq, A. Rahman, D. Wanzer, C.J. Yeo, and R.E. Wilentz A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment Am J Clin Pathol 123 2005 28 35
73. S.V. Tavtigian, J. Simard, J. Rommens, F. Couch, D. Shattuck-Eidens, and S. Neuhausen The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds Nat Genet 12 1996 333 337
74. F. Skoulidis, L.D. Cassidy, V. Pisupati, J.G. Jonasson, H. Bjarnason, and J.E. Eyfjord Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer Cancer Cell 18 2010 499 509
75. A.R. Venkitaraman Cancer susceptibility and the functions of BRCA1 and BRCA2 Cell 108 2002 171 182
76. D.B. Berman, J. Costalas, D.C. Schultz, G. Grana, M. Daly, and A.K. Godwin A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals Cancer Res 56 1996 3409 3414
77. A. Naderi, and F.J. Couch BRCA2 and pancreatic cancer Int J Gastrointest Cancer 31 2002 99 106
78. M.S. van der Heijden, J.R. Brody, D.A. Dezentje, E. Gallmeier, S.C. Cunningham, and M.J. Swartz In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor Clin Cancer Res 11 2005 7508 7515
79. K. Chang, and I. Pastan Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers Proc Natl Acad Sci U S A 93 1996 136 140
80. N.G. Ordonez Application of mesothelin immunostaining in tumor diagnosis Am J Surg Pathol 27 11 2003 1418 1428
81. E. Lutz, C.J. Yeo, and K.D. Lillemoe A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation Ann Surg 253 2 2011 Feb 328 335
82. R. Hassan, S.J. Cohen, M. Phillips, I. Pastan, E. Sharon, and R.J. Kelly Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers Clin Cancer Res 16 24 2010 Dec 15 6132 6138
83. T.M. Williams, and M.P. Lisanti The Caveolin genes: from cell biology to medicine Ann Med 36 2004 584 595
84. C.P. Tanase, S. Dima, M. Mihai, E. Raducan, M.I. Nicolescu, and L. Albulescu Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma J Mol Histol 40 2009 23 29
85. S. Hehlgans, I. Eke, K. Storch, M. Haase, G.B. Baretton, and N. Cordes Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells Radiother Oncol 92 2009 362 370
86. J.R. Mackey, R.S. Mani, M. Selner, D. Mowles, J.D. Young, and J.A. Belt Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res 58 1998 4349 4357
87. T. Okazaki, M. Javle, M. Tanaka, J.L. Abbruzzese, and D. Li Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity Clin Cancer Res 16 2010 320 329
88. J.J. Farrell, H. Elsaleh, M. Garcia, R. Lai, A. Ammar, and W.F. Regine Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer Gastroenterology 136 1 2009 Jan 187 195
89. C.L. Arteaga Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia Semin Oncol 29 2002 3 9
90. H. Immervoll, D. Hoem, K. Kugarajh, S.J. Steine, and A. Molven Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes Virchows Arch 448 2006 788 796
91. S. Cascinu, R. Berardi, R. Labianca, S. Siena, A. Falcone, and E. Aitini Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial Lancet Oncol 9 1 2008 Jan 39 44
92. P.A. Philip, J. Benedetti, C.L. Corless, R. Wong, E.M. O'Reilly, and P.J. Flynn Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 J Clin Oncol 28 22 2010 Aug 1 3605 3610
93. T. Okusaka, J. Furuse, A. Funakoshi, T. Ioka, K. Yamao, and S. Ohkawa Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer Cancer Sci 102 2 2011 Feb 425 431
94. J. Feliu, P. Borrega, A. León, L. López-Gómez, M. López, and J. Castro Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer Cancer Chemother Pharmacol 67 1 2011 Jan 215 221
95. P.Q. Bao, R.K. Ramanathan, A. Krasinkas, N. Bahary, B.C. Lembersky, and D.L. Bartlett Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer Ann Surg Oncol 18 4 2011 Apr 1122 1129
96. N.N. Rahbari, T. Schmidt, C.S. Falk, U. Hinz, M. Herber, and U. Bork Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer BMC Cancer 11 2011 286
97. R. Pezzilli, D. Fabbri, M.M. Corsi, A. Imbrogno, A. Barassi, and A.M. Morselli-Labate Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study Clin Chem Lab Med 49 2011 1047 1051
98. H.L. Kindler, D. Niedzwiecki, D. Hollis, S. Sutherland, D. Schrag, and H. Hurwitz Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303) J Clin Oncol 28 22 2010 Aug 1 3617 3622
99. H.L. Kindler, G. Friberg, D.A. Singh, G. Locker, S. Nattam, and M. Kozloff Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 23 31 2005 Nov 1 8033 8040
100. G.H. Zhu, C. Huang, Z.J. Qiu, J. Liu, Z.H. Zhang, and N. Zhao Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma Dig Dis Sci 56 2011 1090 1098
101. A. Juuti, J. Lundin, S. Nordling, J. Louhimo, and C. Haglund Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer Oncology 71 2006 61 68
102. G. Giannopoulos, K. Pavlakis, A. Parasi, N. Kavatzas, D. Tiniakos, and A. Karakosta The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters Anticancer Res 28 2008 1875 1881
103. U. Tamahashi, J. Kumagai, T. Takizawa, M. Sekine, and Y. Eishi Expression and intracellular localization of matrix metalloproteinases in intraductal papillary mucinous neoplasms of the pancreas Virchows Arch 453 2008 79 87
104. C.L. Wilson, K.J. Heppner, P.A. Labosky, B.L. Hogan, and L.M. Matrisian Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin Proc Natl Acad Sci U S A 94 1997 1402 1407
105. N. Nishikawa, Y. Kimura, K. Okita, H. Zembutsu, T. Furuhata, and T. Katsuramaki Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features J Hepatobiliary Pancreat Surg 13 2006 327 335
106. A. Fukuda, S.C. Wang, J.P. Morris 4th, A.E. Folias, A. Liou, and G.E. Kim Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression Cancer Cell. 19 4 2011 441 455
107. M. Tian, Y.Z. Cui, G.H. Song, M.J. Zong, X.Y. Zhou, and Y. Chen Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients BMC Cancer 8 2008 241
108. T. Koshiba, R. Hosotani, Y. Miyamoto, J. Ida, S. Tsuji, and S. Nakajima Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression Clin Cancer Res 6 2000 3530 3535
109. N. Sato, N. Fukushima, A. Maitra, C.A. Iacobuzio-Donahue, N.T. van Heek, and J.L. Cameron Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas Am J Pathol 164 2004 903 914
110. T. Welsch, S. Keleg, F. Bergmann, L. Degrate, S. Bauer, and J. Schmidt Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma Clin Exp Metastasis 26 2009 701 711
111. Z. Wang, Y. Hao, and A.W. Lowe The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation Cancer Res 68 2 2008 Jan 15 492 497
112. R. Chen, S. Pan, X. Duan, B.H. Nelson, R.A. Sahota, and S. de Rham Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia Mol Cancer 9 2010 Jun 15 149
113. X. He, Z. Zheng, J. Li, Q. Ben, Q. Ben, J. Liu, and J. Zhang DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA Carcinogenesis 33 3 2012 Mar 555 562
114. X.Y. He, B.Y. Liu, W.Y. Yao, X.J. Zhao, Z. Zheng, and J.F. Li Serum DJ-1 as a diagnostic marker and prognostic factor for pancreatic cancer J Dig Dis 12 2 2011 Apr 131 137
115. S. Kostenko, and U. Moens Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology Cell Mol Life Sci 66 20 2009 Oct 3289 3307
116. C. Melle, G. Ernst, N. Escher, D. Hartmann, B. Schimmel, and A. Bleul Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker Clin Chem 53 4 2007 Apr 629 635
117. R. Chen, S. Pan, K. Cooke, K.W. Moyes, M.P. Bronner, and D.R. Goodlett Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis Pancreas 34 1 2007 Jan 70 79
118. S. Takano, K. Sogawa, H. Yoshitomi, T. Shida, K. Mogushi, and F. Kimura Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer Br J Cancer 103 2 2010 Jul 13 223 231
119. C. Bassi, M. Falconi, E. Molinari, R. Salvia, G. Butturini, and N. Sartori Reconstruction by pancreaticojejunostomy versus pancreaticogastrostomy following pancreatectomy: results of a comparative study Ann Surg 242 2005 767 771 [discussion 771-3]
120. M.B. Slidell, D.C. Chang, J.L. Cameron, C. Wolfgang, J.M. Herman, and R.D. Schulick Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis Ann Surg Oncol 15 2008 165 174
121. N. Wasif, C.Y. Ko, J. Farrell, Z. Wainberg, O.J. Hines, and H. Reber Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol 17 2010 2312 2320
122. C. Bassi, D.D. Stocken, A. Olah, H. Friess, J. Buckels, and H. Hickey Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial Dig Surg 22 2005 353 363
123. K.S. Goonetilleke, and A.K. Siriwardena Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer Eur J Surg Oncol 33 2007 266 270
124. W. Steinberg The clinical utility of the CA 19-9 tumor-associated antigen Am J Gastroenterol 85 1990 350 355
125. J.L. Van Laethem, C. Verslype, J.L. Iovanna, P. Michl, T. Conroy, and C. Louvet New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel Ann Oncol 23 3 2012 Mar 570 576
126. F. Giovinazzo, G. Butturini, R. Salvia, G. Mascetta, D. Monsellato, and G. Marchegiani Drain management after pancreatic resection: state of the art J Hepatobiliary Pancreat Sci 18 2011 779 784